14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XOMA vs GERN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Geron Corp (GERN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas GERN carries 60.8/100 (BUY) at $0.96 (51.0x Forward P/E, -7.2% operating margin).
Composite vs. Pillar Nuance: While GERN currently prints a higher short-term Unified Composite Score (60.8/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -7.2% operating margin) and revenue trajectory (-22.6% vs. +27.4% YoY).
Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile GERN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs GERN. Trailing 12-month operating profitability (XOMA -3.9% vs GERN -7.2%) and valuation multiples (XOMA 21.5x vs GERN 51.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $640.4M market capitalization and -7.2% operating margin.
OpEx & R&D Reinvestment69.7% of Rev ($152M)
90D Engineering Disclosures0 Published
Investor FAQ XOMA vs GERN Key Questions & Quantitative Answers
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Geron Corp (GERN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas GERN carries 60.8/100 (BUY) at $0.96 (51.0x Forward P/E, -7.2% operating margin). Composite vs. Pillar Nuance: While GERN currently prints a higher short-term Unified Composite Score (60.8/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -7.2% operating margin) and revenue trajectory (-22.6% vs. +27.4% YoY). Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile GERN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GERN leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with GERN at +27.4% YoY revenue growth and +0.0% YoY earnings growth on $218M TTM revenue (62.5% gross margin, -7.2% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $218M for GERN. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus 69.7% of Rev ($152M) (0 disclosures) for GERN.
XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas GERN trades at 51.0x Forward P/E, 51.0x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-41.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus GERN (-20.1% ROE) capital efficiency.
In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, GERN carries 86.2% implied volatility (15th %ile, Compressed (<25th %ile)), a 3.06x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 101% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.